Niklaus H. Evitt

Niklaus H. Evitt

Auto-generated profile, based on publicly available information

Niklaus H. Evitt

A Stanford University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2018 in Circulation
Verified
Journal Article
Closed access
PDF file
ACAlexandra C. Chadwick
Alexandra C. Chadwick
NENiklaus H. Evitt
Niklaus H. Evitt
WLWenjian Lv
Wenjian Lv
KMKiran Musunuru
Kiran Musunuru

13 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
RGRodrigo A. Gier
Rodrigo A. Gier
KBKrista A. Budinich
Krista A. Budinich
NENiklaus H. Evitt
Niklaus H. Evitt
ZCZhendong Cao
Zhendong Cao
EFElizabeth S. Freilich
Elizabeth S. Freilich
JSJunwei Shi
Junwei Shi
CRISPR-based genetic screening has revolutionized cancer drug target discovery, yet reliable, multiplex gene editing to reveal synergies between gene targets remains a major challenge. Here, we present a simple and robust CRISPR-Cas12a-based approach for combinatorial genetic screening in cancer cells. By engineering the CRISPR-AsCas12a system with key modifications to the Cas protein and its CRISPR RNA (crRNA), we can achieve high efficiency combinatorial genetic screening. We demonstrate the performance of our optimized AsCas12a (opAsCas12a) through double knockout screening against epigenetic regulators. This screen reveals synthetic sick interactions between Brd9&Jmjd6, Kat6a&Jmjd6, and Brpf1&Jmjd6 in leukemia cells.

2 December 2015 in The American Journal of Bioethics
Verified
Journal Article
Open access
NENiklaus H. Evitt
Niklaus H. Evitt
SMShamik Mascharak
Shamik Mascharak
RARuss B Altman
Russ B Altman
CRISPR germline editing therapies (CGETs) hold unprecedented potential to eradicate hereditary disorders. However, the prospect of altering the human germline has sparked a debate over the safety, efficacy, and morality of CGETs, triggering a funding moratorium by the NIH. There is an urgent need for practical paths for the evaluation of these capabilities. We propose a model regulatory framework for CGET research, clinical development, and distribution. Our model takes advantage of existing legal and regulatory institutions but adds elevated scrutiny at each stage of CGET development to accommodate the unique technical and ethical challenges posed by germline editing.

18 October 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
KBKiara N. Berríos
Kiara N. Berríos
NENiklaus H. Evitt
Niklaus H. Evitt
RDRachel A. DeWeerd
Rachel A. DeWeerd
DRDiqiu Ren
Diqiu Ren
MLMeiqi Luo
Meiqi Luo
RKRahul M. Kohli
Rahul M. Kohli

5 June 2015 in Journal of Biological Engineering
Verified
Journal Article
Open access
PDF file
KMKunal K. Mehta
Kunal K. Mehta
NENiklaus H. Evitt
Niklaus H. Evitt
JSJames R. Swartz
James R. Swartz
We have developed a mixture of enzymes and chemicals that completely lyse cyanobacteria. Since the treatment involves only readily-available chemicals and simple proteins that degrade the components of the cyanobacterial cell wall, it can easily be used in high-throughput applications requiring lysis for subsequent intracellular measurements. Our lysis technique consistently enables complete lysis of several different cyanobacterial strains, and we demonstrated that DNA, mRNA, and proteins are preserved in the lysates. Chemical lysis can be superior to existing techniques because of its convenience, reliability, and amenability to a variety of downstream applications.

15 December 2016 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JKJamin Koo
Jamin Koo
TSTim Schnabel
Tim Schnabel
SLSylvie Liong
Sylvie Liong
NENiklaus H. Evitt
Niklaus H. Evitt
JSJames R. Swartz
James R. Swartz